The proteins pairs identified in Figure 3 as having high expression by antigen staining (CDH24, NTRK1, GFRA3, and GPR173) will now serve as the starting point for the development of bispecific CAR-T approaches to neuroblastoma therapy. This evidence concerns the gene GFRA3 and neuroblastoma.